VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2021 | Genomic pathway of gut microbiome predicts efficacy of nivolumab in advanced GC

Yu Sunakawa, MD, PhD, St. Marianna University School of Medicine, Kawasaki, Japan, provides an update on the DELIVER trial, an observational study evaluating nivolumab in patients with advanced gastric cancer (GC) with the aim of investigating whether genomic information the gut microbiome serves as an accurate predictor of response to nivolumab in advanced gastric cancer. The results of the study suggest that bacterial invasion of epithelial cell pathways in the gut microbiome may represent a novel biomarker for treatment with PD-1 checkpoint blockade in patients with advanced gastric cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter